Oral Breast Cancer Drug Wins Broader FDA Nod for ESR1-Mutated Disease

(MedPage Today) — The FDA approved the oral estrogen receptor antagonist imlunestrant (Inluriyo) for previously treated ESR1-mutated advanced/metastatic breast cancer, the agency announced Thursday.
The approval stipulates use in adults with…

Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/117650

Author :

Publish date : 2025-09-25 21:21:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Oral Breast Cancer Drug Wins Broader FDA Nod for ESR1-Mutated Disease

More Evidence for Lower Ribociclib Dose in Advanced Breast Cancer

FDA to Launch Review of Abortion Pill Safety

Related Posts

Lifesaving stem cell centre in Nottingham welcomes first donors

Samaritans facing volunteer exodus over proposed branch closures

Should Kids Stay Away From Tylenol, Too?

FDA to Launch Review of Abortion Pill Safety

More Evidence for Lower Ribociclib Dose in Advanced Breast Cancer

Docs Decry Tylenol Claims; Unsung Healthcare Heroes; ‘I Study, Then Study, Then …’

Lifesaving stem cell centre in Nottingham welcomes first donors

Samaritans facing volunteer exodus over proposed branch closures

Should Kids Stay Away From Tylenol, Too?

FDA to Launch Review of Abortion Pill Safety

Oral Breast Cancer Drug Wins Broader FDA Nod for ESR1-Mutated Disease

More Evidence for Lower Ribociclib Dose in Advanced Breast Cancer

Docs Decry Tylenol Claims; Unsung Healthcare Heroes; ‘I Study, Then Study, Then …’

Nutrition Therapy for Weight Loss: What Works, What Doesn’t

Categories

Archives